These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 18074239)

  • 1. Genetic evaluation of von Hippel-Lindau disease for early diagnosis and improved prognosis.
    Akcaglar S; Yavascaoglu I; Vuruskan H; Oktay B
    Int Urol Nephrol; 2008; 40(3):615-20. PubMed ID: 18074239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation.
    Gomy I; Molfetta GA; de Andrade Barreto E; Ferreira CA; Zanette DL; Casali-da-Rocha JC; Silva WA
    Fam Cancer; 2010 Dec; 9(4):635-42. PubMed ID: 20567917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
    Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
    Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.
    Woodward ER; Clifford SC; Astuti D; Affara NA; Maher ER
    J Med Genet; 2000 May; 37(5):348-53. PubMed ID: 10807693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.
    Foster K; Prowse A; van den Berg A; Fleming S; Hulsbeek MM; Crossey PA; Richards FM; Cairns P; Affara NA; Ferguson-Smith MA
    Hum Mol Genet; 1994 Dec; 3(12):2169-73. PubMed ID: 7881415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifocal bilateral renal cell carcinoma and retinal angiomas in a patient with de novo von Hippel-Lindau disease: identification of a new germline mutation.
    Sessa A; Battini G; Meroni M; Pitingolo F; Righetti M; Ciotti P; Di Maria E; Bellone E; Ajmar F; Mandich P
    J Nephrol; 2005; 18(2):209-12. PubMed ID: 15931650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN.
    Woodward ER; Ricketts C; Killick P; Gad S; Morris MR; Kavalier F; Hodgson SV; Giraud S; Bressac-de Paillerets B; Chapman C; Escudier B; Latif F; Richard S; Maher ER
    Clin Cancer Res; 2008 Sep; 14(18):5925-30. PubMed ID: 18794106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel and recurrent germline mutations in the VHL gene in 5 Arab patients with Von Hippel-Lindau disease.
    Faiyaz-Ul-Haque M; Jamil M; Aslam M; Abalkhail H; Al-Dayel F; Basit S; Nawaz Z; Zaidi SHE
    Cancer Genet; 2020 May; 243():1-6. PubMed ID: 32179488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
    Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
    J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular cytogenetic characterization of early and late renal cell carcinomas in von Hippel-Lindau disease.
    Phillips JL; Ghadimi BM; Wangsa D; Padilla-Nash H; Worrell R; Hewitt S; Walther M; Linehan WM; Klausner RD; Ried T
    Genes Chromosomes Cancer; 2001 May; 31(1):1-9. PubMed ID: 11284029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Juvenile renal cell carcinoma as first manifestation of von Hippel-Lindau disease.
    Granata A; Sessa A; Righetti M; Cordaro S; Leone G; Figura M; Fatuzzo P; Rapisarda F; Di Maria E; Ciotti P; Mandich P; Nardo A; Ferrone M; Gallone S; Liuzzo G
    J Nephrol; 2004; 17(2):306-10. PubMed ID: 15293534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel missense mutation (N78D) in a family with von Hippel-Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts.
    Cingoz S; van der Luijt RB; Kurt E; Apaydin M; Akkol I; Ozgen MH
    Fam Cancer; 2013 Mar; 12(1):111-7. PubMed ID: 23224817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular genetic studies of sporadic and familial renal cell carcinoma.
    Gnarra JR; Glenn GM; Latif F; Anglard P; Lerman MI; Zbar B; Linehan WM
    Urol Clin North Am; 1993 May; 20(2):207-16. PubMed ID: 8098558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic study of a large Chinese kindred with von Hippel-Lindau disease.
    Huang YR; Zhang J; Wang JD; Fan XD
    Chin Med J (Engl); 2004 Apr; 117(4):552-7. PubMed ID: 15109448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
    Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
    Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and molecular features of familial and sporadic cases of von Hippel-Lindau disease from Mexico.
    Chacon-Camacho OF; Rodriguez-Dennen F; Camacho-Molina A; Rasmussen A; Alonso-Vilatela E; Zenteno JC
    Clin Exp Ophthalmol; 2010 Apr; 38(3):277-83. PubMed ID: 20447124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.
    Whaley JM; Naglich J; Gelbert L; Hsia YE; Lamiell JM; Green JS; Collins D; Neumann HP; Laidlaw J; Li FP
    Am J Hum Genet; 1994 Dec; 55(6):1092-102. PubMed ID: 7977367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
    Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
    Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.